抗击AIDS 30年:存活率与机会性感染数据大盘点

2015-06-17 佚名 生物谷

尽管治疗方法的进步减少了艾滋病毒相关的机会性感染的死亡率,但是一份旧金山2万多名AIDS患者的数据分析表明,对于预防与治疗,williamhill asia 还有足够的提升空间。从1997年至2012年间,旧金山仍有三分之一的AIDS病人在诊断为机会性感染后5年内死亡。 为检验HIV治疗的进步是否与典型的AIDS机会性疾病(AIDS-OIs)确诊后存活率的提高有相关性,以及各种AIDS-OIs疾病存活率是否存在差别,

尽管治疗方法的进步减少了艾滋病毒相关的机会性感染的死亡率,但是一份旧金山2万多名AIDS患者的数据分析表明,对于预防与治疗,williamhill asia 还有足够的提升空间。从1997年至2012年间,旧金山仍有三分之一的AIDS病人在诊断为机会性感染后5年内死亡。

为检验HIV治疗的进步是否与典型的AIDS机会性疾病(AIDS-OIs)确诊后存活率的提高有相关性,以及各种AIDS-OIs疾病存活率是否存在差别,研究人员利用旧金山HIV监测数据进行了存活分析,将评估分成在AIDS-OIs诊断开始后的三个治疗阶段:无抗病毒药物阶段1981–1986;单个或双核苷药物治疗阶段1987–1996;高效抗病毒药物治疗阶段1997–2012。其中1997-2012艾滋病机会性感染的死亡率是用Cox比例风险模型确定的。

在20858位艾滋病病人中,诊断频率最高的AIDS-OI为卡氏肺囊虫病和卡波西肉瘤(20.1%)。五年存活率从1981–1986阶段的7%,至1987–1996阶段的18%,提高到1997–2012的65%。“剩余的那些诊断机会性疾病5年内死亡的那35%的人提醒williamhill asia ,应对AIDS-OIs疾病的工作仍旧非常紧迫。即使是有抗逆转录病毒联合治疗的今天,williamhill asia 仍需要更好的预防和诊断策略减轻机会性感染的负担,比如早期HIV诊断。”

研究人员发现,卡氏肺囊虫病,卡波西肉瘤,甚至免疫母细胞淋巴瘤的存活率都显着提升。虽然整体的存活率有所提升,但一些感染如进行性多灶性白质脑病(PML),感染相关癌症包括脑原发淋巴瘤等,直至今日仍有大量的死亡率。

美国疾病预防控制中心、本研究第一作者Kpandja Djawe说,虽然最近的研究表明在美国机会性感染已经不再那么常见和致命,williamhill asia 也不能忘记这仍是个严重的问题。旧金山应该是AIDS机会性感染的死亡率下降的最好例子,是少数几个最早阶段发展有效的社区宣传和提供健康护理的城市。美国其他地区面临比旧金山更严峻的挑战。艾滋病的流行已经从东西海岸的特大城市传播到小城镇、中西部、南部和乡村。他们不得不面对护理经验不足,病人人种复杂的种种困难,辖区缺乏广泛的HIV检测排查资源也使感染病人难以尽早开始有效治疗。

总的来说,自从上世纪80年代早期HIV病毒被鉴定出来,williamhill asia 已经取得了抗击HIV的可喜成果,旧金山的研究报告鼓舞人心,但机会性感染造成的灾难性疾病仍旧值得关注。



原始出处:


Masur H1, Read SW2.Opportunistic Infections and Mortality: Still Room for Improvement.J Infect Dis. 2015 Jun 3. pii: jiv236. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033823, encodeId=4af32033823fc, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sat Jul 18 14:08:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29260, encodeId=461029260b1, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:14:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862885, encodeId=03de186288593, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Mon Aug 03 17:08:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365614, encodeId=4ab21365614eb, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Fri Jun 19 01:08:00 CST 2015, time=2015-06-19, status=1, ipAttribution=)]
    2015-07-18 wjywjy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033823, encodeId=4af32033823fc, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sat Jul 18 14:08:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29260, encodeId=461029260b1, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:14:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862885, encodeId=03de186288593, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Mon Aug 03 17:08:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365614, encodeId=4ab21365614eb, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Fri Jun 19 01:08:00 CST 2015, time=2015-06-19, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2033823, encodeId=4af32033823fc, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sat Jul 18 14:08:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29260, encodeId=461029260b1, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:14:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862885, encodeId=03de186288593, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Mon Aug 03 17:08:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365614, encodeId=4ab21365614eb, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Fri Jun 19 01:08:00 CST 2015, time=2015-06-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2033823, encodeId=4af32033823fc, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sat Jul 18 14:08:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29260, encodeId=461029260b1, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:14:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862885, encodeId=03de186288593, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Mon Aug 03 17:08:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365614, encodeId=4ab21365614eb, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Fri Jun 19 01:08:00 CST 2015, time=2015-06-19, status=1, ipAttribution=)]
    2015-06-19 cooco

相关威廉亚洲官网

2014 HIV/AIDS 领域大事盘点

编者按:2014年,对于关注艾滋病毒/艾滋病(HIV/AIDS)医学领域的人来说,既有好消息又有坏消息:HIV重现打碎 “密西西比婴儿”治愈奇迹;包括前国际艾滋病协会主席乔普•朗格(Joep Lange)及其夫人在内的6名专家在马航MH17空难中丧生;美国与几个欧洲国家一起弄清了人类第一例艾滋病发生在何处,是何时以及如何发生的;HIV新感染者少于新获治疗者,全球

FDA批准用于HIV/AIDS患者抗腹泻药

    2012年12月31日,美国食品与药物管理局(FDA)批准了Fulyzaq(crofelemer)用以减轻接受抗逆转录病毒联合治疗的HIV / AIDS患者腹泻症状。该药是植物处方药,其活性成分来自龙血巴豆(Croton lechleri)汁液。   许多患者停止或转换抗逆转录病毒药物治疗是因为腹泻的原因。Fulyzaq预期用于治疗非

AIDS 2014:抗逆转录病毒药物疗法新近进展(MODERN试验)

葛兰素史克(GSK)和辉瑞(Pfizer)合资公司ViiV Healthcare 7月22日在澳大利亚墨尔本举行的第20届国际艾滋病大会上公布了III期MODERN研究48周结果的分析数据,该项研究在抗逆转录病毒药物初治(antiretroviral-naïve)HIV患者中开展,将maraviroc(MVC,马拉韦罗,商品名Celsentri/Selzentry,一种口服CCR5进入抑制剂)+达